Asia Pacific Preclinical Cro Market Size & Outlook
Global Market
Related Markets
Asia Pacific preclinical cro market highlights
- The Asia Pacific preclinical cro market generated a revenue of USD 1,093.7 million in 2025.
- The market is expected to grow at a CAGR of 9.8% from 2026 to 2033.
- In terms of segment, preclinical optimization, efficacy & pk/pd was the largest revenue generating development stage in 2025.
- Early CMC / Phase I–II Supply is the most lucrative development stage segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 1,093.7 million |
| Market revenue in 2033 | USD 2,290.3 million |
| Growth rate | 9.8% (CAGR from 2026 to 2033) |
| Largest segment | Preclinical optimization, efficacy & pk/pd |
| Fastest growing segment | Early CMC / Phase I–II Supply |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Target Discovery, Preclinical Optimization, Efficacy & PK/PD, IND-Enabling Safety (GLP), Bioanalysis & Analytics, Early CMC / Phase I–II Supply |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 16.3% of the global preclinical cro market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,290.3 million by 2033.
The changing business model of MNC outsourcing and the rising cost of R&D is expected to increase preclinical outsourcing in Asia Pacific owing to cost efficiency offered by CROs in countries such as India and China. Established companies located in Western Europe and the U.S. pursue analytical services, site research development, and clinical activities in the Asia Pacific region.
The establishment of several CROs across the Asia Pacific region has also strengthened the preclinical trial outsourcing market in this region. For instance, Singapore has several CROs to support the growing needs of pharmaceutical and biopharmaceutical companies. Some of these CROs include IQVIA and ICON, which manage regional preclinical and clinical trials from Singapore.
Growth in the market is due to the advanced healthcare infrastructure in the region. Moreover, an increasing number of CROs are focusing on partnerships and investments. Likewise, the development of outsourcing hubs, the expansion of market players along with the availability of skilled practitioners further contribute to the growth of the market.
No credit card required*
Publish Date: Apr 23, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Eurofins Scientific SE | View profile | 61,798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | www.eurofins.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Icon PLC | View profile | 41,150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | www.iconplc.com |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Medpace Holdings Inc | View profile | 5,800 | 5375 Medpace Way, Cincinnati, OH, United States, 45227 | www.medpace.com |
| Intertek Group PLC | View profile | 44,000 | 33 Cavendish Square, London, United Kingdom, W1G 0PS | www.intertek.com |
| Crown Bioscience | View profile | 251-500 | Santa Clara, California, United States, North America | www.crownbio.com |
| SGA | View profile | 11-50 | Las Condes, Region Metropolitana, Chile, South America | sgasa.cl |
Asia Pacific Preclinical CRO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Preclinical CRO Market Outlook will help companies and investors design strategic landscapes.
Preclinical Optimization, Efficacy & Pk/Pd was the largest segment with a revenue share of 35.87% in 2025.
Horizon Databook has segmented the Asia Pacific preclinical cro market based on target discovery, preclinical optimization, efficacy & pk/pd, ind-enabling safety (glp), bioanalysis & analytics, early cmc / phase i–ii supply covering the revenue growth of each sub-segment from 2021 to 2033.
The changing business model of MNC outsourcing and the rising cost of R&D is expected to increase preclinical outsourcing in Asia Pacific owing to cost efficiency offered by CROs in countries such as India and China. Established companies located in Western Europe and the U.S. pursue analytical services, site research development, and clinical activities in the Asia Pacific region.
The establishment of several CROs across the Asia Pacific region has also strengthened the preclinical trial outsourcing market in this region. For instance, Singapore has several CROs to support the growing needs of pharmaceutical and biopharmaceutical companies. Some of these CROs include IQVIA and ICON, which manage regional preclinical and clinical trials from Singapore.
Growth in the market is due to the advanced healthcare infrastructure in the region. Moreover, an increasing number of CROs are focusing on partnerships and investments. Likewise, the development of outsourcing hubs, the expansion of market players along with the availability of skilled practitioners further contribute to the growth of the market.
- Asia Pacific Preclinical Cro Market Development Stage Outlook (Revenue, USD Million , 2021-2033)
- Target Discovery
- Preclinical Optimization, Efficacy & PK/PD
- IND-Enabling Safety (GLP)
- Bioanalysis & Analytics
- Early CMC / Phase I–II Supply
- Asia Pacific Preclinical Cro Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- CNS
- Infectious Diseases
- Cardiovascular Diseases
- Metabolic Disorders
- Rare Diseases
- Others
- Asia Pacific Preclinical Cro Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical and Biopharmaceutical Companies
- Medical Device Companies
- Academic and Research Institutes
- Others
Reasons to subscribe to Preclinical CRO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Preclinical CRO Market Outlook databook
- Our clientele includes a mix of Preclinical CRO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Preclinical CRO Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Preclinical CRO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Preclinical Cro Market, 2021-2033 (US$M)
Asia Pacific Development Stage - Preclinical Cro Market Statistics, 2025 - 2033 (US$M)
